Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.
Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.
复制标题
已批准的顺铂衍生物在联合治疗不同癌症疾病中的应用。
DOI：
10.3390/molecules27082466
复制
发表时间：
2022-04-11
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
抗癌治疗的问题是耐药性和毒性。从3000顺铂衍生物作为抗肿瘤剂测试，他们中的大多数已被拒绝，由于毒性。本研究的目的是比较目前临床实践中应用的治疗组合：顺铂、卡铂、奥沙利铂、奈达铂、洛铂、七铂和赛特铂。文献数据显示，开发铂类抗癌药物和绕过顺铂衍生物耐药性及其毒性的策略为：联合治疗、Pt IV前药、靶向纳米载体。提高对不同癌症的抗肿瘤效果的非常重要的策略是顺铂衍生物与以下的协同组合：（1）抗癌剂-氟尿嘧啶、吉西他滨、阿糖胞苷、氟达拉滨、培美曲塞、异环磷酰胺、伊立替康、拓扑替康、依托泊苷、氨柔比星、阿霉素、表柔比星、长春瑞滨、多西他赛、紫杉醇、Nab-紫杉醇;（2）抗性机制的调节剂;（4）免疫抑制剂药物-阿特珠单抗、阿维单抗、贝伐单抗、Cemiplimab、西妥昔单抗、Durvalumab、厄洛替尼、伊马替尼、Necitumumab、尼妥珠单抗、Nivolumab、Onartuzumab、帕尼单抗、派姆单抗、曲妥珠单抗、曲美木单抗和Sintiliumab。用于克服顺铂衍生物的耐药性和降低其毒性的一种重要方法是应用纳米载体（聚合物和脂质体），其提供改进的靶向递送、增加的细胞内渗透、在肿瘤组织中的选择性积累和增强的治疗功效。联合治疗的优点是最大限度地去除不同阶段的肿瘤细胞;防止耐药;抑制肿瘤细胞及其突变的适应;并降低毒性。
The problems with anticancer therapy are resistance and toxicity. From 3000 Cisplatin derivatives tested as antitumor agents, most of them have been rejected, due to toxicity. The aim of current study is the comparison of therapeutic combinations of the currently applied in clinical practice: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, Lobaplatin, Heptaplatin, and Satraplatin. The literature data show that the strategies for the development of platinum anticancer agents and bypassing of resistance to Cisplatin derivatives and their toxicity are: combination therapy, Pt IV prodrugs, the targeted nanocarriers. The very important strategy for the improvement of the antitumor effect against different cancers is synergistic combination of Cisplatin derivatives with: (1) anticancer agents—Fluorouracil, Gemcitabine, Cytarabine, Fludarabine, Pemetrexed, Ifosfamide, Irinotecan, Topotecan, Etoposide, Amrubicin, Doxorubicin, Epirubicin, Vinorelbine, Docetaxel, Paclitaxel, Nab-Paclitaxel; (2) modulators of resistant mechanisms; (3) signaling protein inhibitors—Erlotinib; Bortezomib; Everolimus; (4) and immunotherapeutic drugs—Atezolizumab, Avelumab, Bevacizumab, Cemiplimab, Cetuximab, Durvalumab, Erlotinib, Imatinib, Necitumumab, Nimotuzumab, Nivolumab, Onartuzumab, Panitumumab, Pembrolizumab, Rilotumumab, Trastuzumab, Tremelimumab, and Sintilimab. An important approach for overcoming the drug resistance and reduction of toxicity of Cisplatin derivatives is the application of nanocarriers (polymers and liposomes), which provide improved targeted delivery, increased intracellular penetration, selective accumulation in tumor tissue, and enhanced therapeutic efficacy. The advantages of combination therapy are maximum removal of tumor cells in different phases; prevention of resistance; inhibition of the adaptation of tumor cells and their mutations; and reduction of toxicity.
登录
查看更多内容
影响因子：
24.5
作者：
Arnold, Melina;Ferlay, Jacques;Soerjomataram, Isabelle
通讯作者：
Soerjomataram, Isabelle
影响因子：
5.5
作者：
Bacchetti, Tiziana;Salvolini, Eleonora;Emanuelli, Monica
通讯作者：
Emanuelli, Monica
影响因子：
4.6
作者：
Ahn, Myung-Ju;Oh, Ho-Suck;Kwon, Sung-Joon
通讯作者：
Kwon, Sung-Joon
影响因子：
3.5
作者：
Basaran, Mert;Bavbek, E. Sevil;Onat, Haluk
通讯作者：
Onat, Haluk
影响因子：
7.3
作者：
Baba H;Yamada Y;Takahari D;Matsumoto H;Yoshida K;Nakamura M;Yoshida M;Iwamoto S;Shimada K;Komatsu Y;Sasaki Y;Satoh T;Takahashi K;Mishima H;Muro K;Watanabe M;Sakata Y;Morita S;Shimada Y;Sugihara K
通讯作者：
Sugihara K